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Abstract
Cancer patient survival is the single most important measure of cancer patient care.
By quantifying cancer patient survival in different ways further insights can be gained
in terms of temporal trends and differences in cancer patient survival between groups.
The objective of this thesis is to develop and apply methods for estimating the cure
proportion and loss in expectation of life for cancer patients.
In paper I, a cure model was used to study temporal trends in survival of patients
with acute myeloid leukaemia in Sweden. Cancer patient survival was estimated in a
relative survival setting and quantified as the proportion cured and the median survival
time of uncured for different age groups and by calendar time of diagnosis. We found
a dramatic increase in the cure proportion for the age group 19-40, although almost
no improvement was seen for patients aged 70-79 at diagnosis.
In paper II, a flexible parametric cure model was developed to overcome some
limitations with standard parametric cure models. This model is a special case of
a non-mixture cure model, using splines instead of a parametric distribution for the
modeling. The fit of the flexible parametric cure model was compared to the fit of a
Weibull non-mixture cure model, and shown to be superior in cases when the standard
non-mixture cure model did not give a good fit or did not converge. Software was
developed to enable use of the method.
In paper III, the possibility of using a flexible parametric relative survival model for
estimating life expectancy and loss in expectation of life was evaluated. Extrapolation
of the survival function is generally needed, and the flexible parametric relative survival
model was shown to extrapolate the survival very well. The method was evaluated by
comparing survival functions extrapolated from 10 years past diagnosis to observed
survival by the use of data with 40 years of follow-up. Software was developed to
enable use of the method.
In paper IV, the life expectancy and loss in expectation of life was estimated for
colon cancer patients in Sweden. Even though relative survival was similar across age
for colon cancer patients, the loss in expectation of life varied greatly by age, since
young patients have more years to lose. We also found that the life expectancy of
colon cancer patients improved over time. However, the improvement has to a large
extent mimicked the improvement seen in the general population, and therefore there
were no large changes in the loss in expectation of life.
In conclusion, the methods presented in this thesis are additional tools for esti-
mating and quantifying population-based cancer patient survival, that can lead to an
improved understanding of different aspects of the prognosis of cancer patients.
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1 Introduction
Data from cancer registries are used to measure the incidence of cancer, cancer mortality
and the prognosis of cancer patients. Cancer patient survival is the single most important
measure of cancer patient care (the diagnosis and treatment of cancer) and is of considerable
interest to clinicians, patients and researchers. There is, however, room for improvement to
the statistical methods currently used to estimate cancer patient survival. Cancer patient
survival is often reported as the 5-year relative survival, the proportion of patients still alive
5 years after diagnosis if cancer was the only possible cause of death [1]. Even though there
are alternative less simplistic measures, of more relevance to patients and clinicians, they
have not yet been widely used.
Relative survival is defined as the ratio of the observed survival to the expected survival.
Excess mortality is the mortality analogue of relative survival. It is often of interest to
model the excess mortality rate to compare different groups. This is often done using Poisson
regression and results are presented as excess hazard ratios [2]. This is a relative measure and
does not provide an estimate of absolute risk. The popularity of presenting hazard ratios,
from Poisson regression (or Cox regression for cause-specific survival) has led to researchers
thinking less about absolute measures of risk and therefore the impact a potential risk factor
has on both the individual and the population. The flexible parametric survival model
[3, 4, 5] is an alternative model that models rates in an improved way, by directly modelling
the effect of time using restricted cubic splines [6, 7]. In addition, time-dependent effects can
easily be incorporated and the models also enable the results to be displayed in a number of
ways that aid the understanding of individual risk and the impact on the whole population.
Flexible parametric survival models have been extended to a relative survival framework,
allowing the modelling of excess mortality [8].
This PhD project focuses on estimation of cancer patient survival in a population-based
setting. I have extended the flexible parametric survival model to enable estimation of alter-
native measures of cancer patient survival, namely cure and loss in expectation of life. An
important task for biostatisticians is to communicate the results from complicated statisti-
cal methods in a way that is understandable for other researchers, clinicians and healthcare
policymakers. Therefore, I have also applied novel methods for estimation of cancer patient
survival to cancer registry data to present the methodology to a broader audience.
This thesis combines the development of statistical methods for population-based cancer
survival studies, development of user-friendly software to facilitate wide application of the
methods as well as applications of methods for population-based cancer survival studies to
data from cancer registries.
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2 Background
2.1 What is cancer?
Cancer is not one disease, but a broad group of about 200 different diseases that all arise
because of uncontrolled growth of cells in the body. Different types of cancer have different
etiology, symptoms and prognosis. Cancer cells invade the tissue around the tumour and
often have the ability to spread to other parts of the body. When the cancer has spread
and developed tumours at other locations in the body these are referred to as metastasis, as
opposed to the original tumour, which is often referred to as a primary tumour. The cells
in the metastatic, or secondary, tumours are similar to those in the primary tumour, and it
is the origin of the primary tumour that determines the type of cancer. For example, if a
breast cancer metastasises to the lung, the tumours in the lung are metastatic breast cancer
and not lung cancer.
In 2008 more than 12 million cancer cases occurred worldwide, and 7.6 million cancer
deaths [9]. Cancer is the leading cause of death in many economically developed countries,
and the second leading cause of death in many other countries, including many economically
developing countries. The most common cancer among females worldwide is breast cancer,
and it is also the cancer leading to most deaths. Among males the most common cancers
are lung (the most common in developing countries) and prostate cancer (the most common
in developed countries), and lung cancer is the cancer leading to most deaths. In Sweden,
cancer is the second most common cause of death after cardiovascular diseases [10]. In 2011,
almost 58 000 cancers were diagnosed in Sweden, and almost 23 000 deaths were attributed
to cancer [11]. The most common cancers in Sweden are prostate cancer (9 663 cases in 2011)
and breast cancer (8 427 cases). Other common cancers are non-melanoma skin cancer, colon
cancer and lung cancer.
2.2 Cancer registries
The task of population-based cancer registries is to collect and store information on all
diagnosed cases of cancer in a region or a country as well as producing statistics of the
occurrence of cancer and the survival of cancer patients. They play an important role in
analyzing the impact of cancer and the cancer care in the society, and how it changes over
time [12, 13, 14]. There are three commonly reported outcome measures estimated from
cancer registry data; incidence, mortality and survival [1]. Cancer incidence is a measure of
how frequently the cancer is diagnosed and is often measured as the number of new cases
per 100 000 person-years. Cancer incidence is an important measure of the cancer burden.
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Cancer mortality measures deaths due to cancer in the whole population and is also given as
a rate (often per 100 000 person-years). Cancer mortality provides another measure of the
cancer burden, and is often presented together with the incidence to give a more complete
picture of the cancer burden. Since cancer mortality reflects changes in cancer incidence as
well as changes in cancer survival there are difficulties in using it to analyse cancer care.
Moreover, both the incidence and the mortality are heavily influenced by the distribution
of risk factors in the population, whereas the survival is not affected by the distribution of
risk factors to the same extent. Improvements in cancer care, the diagnosis and treatment
of cancer, are best monitored using the survival among those diagnosed with cancer.
In this thesis data from the Swedish Cancer Registry (paper I, III and IV) and the Finnish
Cancer Registry (paper II) were analysed. More information about the registries is given in
Section 5.
2.3 Cancer patient survival
Cancer patient survival is measured by the time between diagnosis and death due to cancer,
and is often summarised as the proportion of patients surviving the cancer up to a certain
point, often 5 years, after diagnosis. Cancer patient survival often aims at estimating net
survival [1], sometimes called marginal survival [15]. Net survival is interpreted as the
proportion of patients that survive in the hypothetical scenario where the cancer of interest
is the only possible cause of death. So, the 5-year survival is an estimate of the proportion
of patients still alive five years after diagnosis if the cancer of interest is the only possible
cause of death. For most types of cancer 5-year survival has increased over the last few
decades, indicating that cancer treatment has improved. Different research questions, and
different consumers of cancer patient survival statistics, need different measures of survival,
since there is no“one-size-fits-all”measure. Therefore, it is important that alternatives to the
5-year survival proportion are considered. One alternative measure is the cure proportion,
the proportion of patients that will not experience excess mortality due to the diagnosed
cancer. Another measure is the life expectancy among cancer patients and the loss in life
expectancy due to the diagnosed cancer. Estimation of cure and the loss in expectation of
life is the main focus of the studies included in this thesis, and will be described in detail in
the following sections.
One problem with survival is that it can be affected by lead-time bias. Lead-time is
survival time that is added to a patient’s survival time because of an earlier diagnosis irre-
spective of a possibly postponed time of death. In the presence of lead-time, the survival
time of the patients is prolonged by an earlier diagnosis, and the survival proportion at any
given time point is therefore increased even if no real improvement in survival is experi-
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enced. This is referred to as lead-time bias. When a cancer is diagnosed earlier, there is
usually a better chance of surviving the cancer or postponing death, which will also lead
to an improved survival. Therefore, it can be difficult to disentangle how much of an ob-
served improvement is due to lead-time and how much is due to an actual improvement in
survival. The possibility of lead-time should always be taken into account when comparing
survival proportions between groups or over calendar time, especially for cancers that can
be detected by screening. This is one of the reasons why it is very difficult to evaluate the
effectiveness of screening programmes in improving cancer patient survival. Even so, cancer
patient survival is the principal measure of the effectiveness of cancer care, and all studies
in this thesis concern measures of cancer patient survival.
2.4 Survival analysis
All of the studies in this thesis concern the estimation of cancer patient survival, and before
describing the methods used, a brief introduction to survival analysis is given in this chapter.
Survival analysis is used to study the time, T , to occurrence of some event of interest [16].
In cancer patient survival that refers to time from diagnosis of cancer until death due to
cancer.
It is usually not possible to follow all patients until the event of interest (death due to
cancer) occurs, and when this is the case the survival time is censored at the last available
follow-up time. This type of censoring, when the event is known to have not happened at
last follow-up time, is referred to as right-censoring. There are different types of censoring,
but in population-based cancer patient survival right-censoring is most common, and is the
only type of censoring considered in this thesis. To distinguish between event times and
censoring times all patients have, in addition to the observed time ti, an event indicator di
that takes the value 1 if the patient experienced the event and 0 if censored.
In addition to the density function, f(t), and the cumulative distribution function, F (t),
there are three important functions to describe T . These are the survival function, the hazard
function and the cumulative hazard function. The survival function gives the probability
that the survival time is greater than time t, which is the same as 1 minus the cumulative
distribution function
S(t) = P (T > t) = 1− F (t). (1)
The survival function is non-increasing and can only take values between 0 and 1. The
hazard function is defined as the event rate at time t conditional on surviving up until time
t,
h(t) = lim
∆t→0
P (t ≤ T < t+ ∆t|T ≥ t)
∆t
. (2)
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The cumulative hazard function is the integrated hazard function,
H(t) =
∫ t
0
h(u)du. (3)
Although hard to interpret in itself, the cumulative hazard function is a useful function, for
example when modelling. In the flexible parametric survival model (described in section 2.6)
modelling is performed on the log cumulative hazard scale.
All the functions above are mathematically related, and some important relationships
are presented here.
S(t) = exp(−H(t)) = exp
[
−
∫ t
0
h(u)du
]
(4)
h(t) =
d
dt
H(t) = f(t)/S(t) = −d ln(S(t))/dt = −S ′(t)/S(t). (5)
2.5 Relative survival
The method of choice for estimating cancer patient survival in a population-based setting is
relative survival, R(t) [1, 17], and the most common summary measure for cancer patient
survival is the 5-year relative survival ratio (RSR). Relative survival is defined as the observed
(all-cause) survival, S(t), among the cancer patients divided by the expected survival, S∗(t),
the patients would have experienced had they not had cancer. The expected survival is
typically obtained from nationwide population mortality rates (also called population life
tables), stratified by age, sex, calendar year and possibly other covariates. The Human
Mortality Database (HMD) [18, 19] contains population life tables for 37 countries, and the
population life tables used for the studies in this thesis were all extracted from HMD. If
the relative survival is lower than one, the cancer patients have a worse survival than a
comparable group in the general population, and this is assumed to be due to the cancer
under study. A relative survival of 1 suggests that the cancer patients have the same survival
as a comparable group in the general population, but it does not mean that 100% of the
cancer patients are still alive. In the relative survival setting the overall survival, as a function
of time t since diagnosis, is written as
S(t) = S∗(t)R(t). (6)
The main reason for using relative survival (instead of cause-specific survival where only
deaths due to the cancer of interest are considered events and deaths due to other causes
are censored) is that it does not rely on correct classification of cause of death. The cause
of death can be poorly reported, especially among elderly patients [20], and even when the
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reporting is good it can be difficult to determine if the death of a cancer patient is due to the
cancer of interest or not (for example death from treatment complications) [21]. All studies
included in this thesis use relative survival.
Relative survival will give an estimate of the net survival of interest if the cancer patients
are exchangeable with the general population and there are no factors associated with both
cancer and non-cancer mortality other than those factors that are both adjusted for in the
analysis and in the population mortality file. If the cancer patients are not exchangeable
with the general population the discrepancy between the observed and the expected survival
can not be fully explained by the cancer and if the cancer and non-cancer mortality are not
independent (given the factors adjusted for) the relative survival will not give an unbiased
estimate of the net survival [22, 23, 24, 25].
The hazard analogue of relative survival is excess hazard, and it measures the mortality
the patients experience in excess of what would be expected if they had not had cancer. The
overall hazard, h(t), among the patients is written as the sum of the expected hazard, h∗(t),
and the excess hazard, λ(t), associated with the cancer
h(t) = h∗(t) + λ(t). (7)
The overall as well as the relative survival can vary by covariates, z, for example patient
characteristics such as sex, age and calendar year of diagnosis, as well as tumour character-
istics such as stage or grade. The expected mortality is allowed to vary by the stratification
factors given in the population mortality rates, denoted with z
′
, which are usually a subset
of z. Equation (6) and (7) are then extended as follows,
S(t; z) = S∗(t; z
′
)R(t; z), and (8)
h(t; z) = h∗(t; z
′
) + λ(t; z). (9)
Different regression models have been suggested for modelling the excess hazard, but most
of the methods require follow-up time to be split into pre-specified time-bands or numerical
integration [2, 26, 27, 28, 29]. Extensions of the Cox proportional hazards model have also
been suggested for modelling of the excess hazard [30, 31], but unlike the standard Cox
model the baseline is needed in the estimation. An alternative approach, which enables the
modelling of time continuously and easily incorporates time-dependent effects, is the flexible
parametric survival model [3, 4, 5]. The flexible parametric survival model has been extended
to a relative survival setting [8]. The flexible parametric relative survival model is used in
paper II-IV, and will be explained in the following sections.
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2.6 The flexible parametric survival model
The flexible parametric survival model was first introduced by Royston and Parmar in 2001
[3, 4]. The model is fitted on the log cumulative hazard scale, using restricted cubic splines
[6, 7] to estimate the baseline log cumulative hazard. Splines are piecewise polynomial
functions (of order 3 for cubic splines) that are forced to have continuous first and second
derivatives at the joining points, called knots. This ensures a smooth function. Restricted
cubic splines are cubic splines forced to be linear beyond the boundary knots, to make the
estimated function less influenced by sparse data in the tail of the distribution. Before
extending the flexible parametric survival model to a relative survival framework in the next
section, the general model is explained here.
The log cumulative hazard is modelled as a function of follow-up time, t, as
ln(H(t)) = s(x;γ0) (10)
where x = ln(t) and s(x;γ0) is a restricted cubic spline function. The latter is defined as
s(x;γ0) = γ00 + γ01v1(x) + γ02v2(x) + ...+ γ0K−1vK−1(x), (11)
where K is the number of knots and the pth basis function is defined as
vp(x) =
x, for p = 1(x− kp)3+ − λp(x− k1)3+ − (1− λp)(x− kK)3+, for p = 2, ..., K − 1 (12)
where u+ = u if u > 0 and u+ = 0 if u ≤ 0, k1 is the position of the first knot, kK the
position of the last knot, kp the position of the p
th knot, and λp =
kK−kp
kK−k1 .
Introducing covariates, z, into equation (10) gives
ln(H(t; z)) = s(x;γ0) + zβ. (13)
This is a proportional hazards model, so covariate effects, β, are interpreted in the same
way as for models on the log hazard scale. If s(x;γ0) is a linear function of x, this is a
Weibull model. So, the flexible parametric survival model is similar to a Weibull model but
instead of modelling the log cumulative hazard as a linear function of log time it is modelled
with the use of splines. Since a restricted cubic spline is used in the flexible parametric
survival model, the log cumulative hazard is a linear function of log time after the last knot.
Therefore, the flexible parametric survival model behaves like a Weibull distribution in the
tail. Non-proportional hazards, i.e, time-dependent covariate effects, can be modelled by
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including interactions between covariates and spline functions for log time. Modelling of the
departure from a time-fixed effect usually does not require as many knots as modelling of
the baseline cumulative hazard. Therefore a new set of spline parameters are introduced for
each time-dependent effect, and separate knot positions can be chosen for each covariate, zi,
with a time-dependent effect. This gives the model:
ln(H(t; z)) = s(x;γ0) + zβ +
D∑
i=1
s(x;γi)zi, (14)
where D is the number of time-dependent covariate effects and s(x;γi) is the spline function
for the ith time-dependent effect.
Estimation is performed by maximum likelihood. The general log-likelihood for right-
censored survival data can be expressed as:
lnL =
N∑
i=1
di ln[h(ti; zi)] + ln[S(ti; zi)], (15)
where N is the number of individuals, di = 1 for an event (e.g. death) and 0 for censored
observations. Let η = ln(H(t; z)) where ln(H(t; z)) is expressed as in equation (13) or (14),
then the survival function and the hazard function are expressed by their relationship with
the log cumulative hazard function as
S(t; z) = exp(− exp(η)), and (16)
h(t; z) =
d
dt
exp(η). (17)
The hazard function requires derivatives of the spline functions, and they can easily be
obtained analytically [3]. Since both the survival and the hazard functions can be obtained
analytically, numerical integration is not needed, which speeds up computation time. This is
one of the reasons for fitting the flexible parametric model on the log cumulative hazard scale.
Another reason is that the log cumulative hazard function is a relatively stable function, so
it is easy to capture it’s shape with the use of splines.
The number and location of the knots in the flexible parametric survival model has to be
defined by the user, and in my experience 4-6 knots is usually sufficient to capture the shape
of the log cumulative hazard. Flexible parametric survival models have been implemented in
Stata (Statacorp, College Station, TX) [32] in the package stpm2 [5]. In this implementation
the default knot distribution is according to centiles of the log event times with the first knot
at the first observed event time and the last knot at the last event time. If, for example, 6
8
knots are used the knots are placed at the 0th, 20th, 40th, 60th 80th and 100th percentile
of event times. By placing the boundary knots at the first and last event times there is no
linearity assumption within the range of the data. The user can instead of using the default
positions explicitly position the knots, either by specifying other percentiles or by specifying
time points (in years of follow-up) for the positions of the knots. Sensitivity to the knot
distribution has been evaluated, and the flexible parametric survival model has been shown
to be insensitive to both the number and location of the knots [33, 34].
2.7 The flexible parametric survival model for relative survival
The flexible parametric survival model has been extended to relative survival [8], and the
extended model is used in studies II-IV. By integrating equation (9), the overall cumulative
hazard, H(t), is expressed as
H(t; z) = H∗(t; z
′
) + Λ(t; z), (18)
where H∗(t) is the cumulative expected hazard and Λ(t) is the cumulative excess hazard. In
a flexible parametric survival model for relative survival, Λ(t; z) is modelled using splines in
the same manner as described for H(t; z) in section 2.6.
The log-likelihood for relative survival is expressed as
lnL =
N∑
i=1
di ln[h
∗(ti; z
′
i) + λ(ti; zi)] + ln[S
∗(ti; z
′
i)] + ln[R(ti; zi)]. (19)
Since S∗(ti; z
′
) is not dependent on any of the unknown model parameters it can be removed
from the log likelihood,
lnL =
N∑
i=1
di ln[h
∗(ti; z
′
i) + λ(ti; zi)] + ln[R(ti; zi)], (20)
so the only background information needed is the expected rate at event times for those who
die. The relative survival, R(t; z), and excess hazard, λ(t; z), can be obtained analytically as
described in equations (16) and (17), where η now refers to the log cumulative excess hazard
function, Λ(t; z), as opposed to the log cumulative hazard function.
2.8 Cure models
For many types of cancer the mortality among the patients will eventually return to the
same level as in the general population, i.e. R(t) reaches a plateau (as seen in Figure 1) and
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λ(t) reaches zero at some time point after diagnosis. This point in time is called the cure
point and the patients still alive at this point are considered “statistically cured”. This is a
population definition of cure and does not necessarily imply that all patients are medically
cured. Statistical cure is not estimated on an individual basis, but gives an estimate of the
proportion of patients that will not experience excess mortality due to the cancer, and can
be of interest for measuring long-term survival in population-based cancer studies. The two
most commonly used cure models in population-based studies are described in the following
sections.
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Figure 1 – Hypothetical relative survival curve where the estimated cure proportion is 0.4.
Mixture cure model
One of the most commonly used cure models in population-based cancer studies is the
mixture cure model [35, 36, 37, 38, 39, 40, 41], and it is the model used in paper I. The
model assumes that a proportion, pi, are not at risk of experiencing the event (i.e. dying due
to the diagnosed cancer) and are therefore considered cured. The other proportion, 1 − pi,
are the uncured and will, in the absence of censoring, experience the event. Their survival
function associated with the disease will therefore tend to zero. In a relative survival setting
the overall survival function for the mixture cure model is written as
S(t; z) = S∗(t; z
′
)(pi(z) + (1− pi(z))Su(t; z)), (21)
where Su(t; z) is the cancer-specific survival function for the uncured, for which a parametric
distribution is usually chosen, and a Weibull distribution is often used [37, 38, 42, 43, 44].
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The covariates, z, included for modelling the cure proportion, pi, and the survival of uncured,
Su(t), can be different. For example, the survival distribution of uncured can depend on only
a subset of the covariates included to model the cure proportion, or the survival distribution
of the uncured can be assumed to not vary by covariates at all. For simplicity, I will continue
to refer to the covariates as z for both the cure proportion and the survival distribution of
uncured, and in most cases it is recommended to include all covariates of interest in the
modelling of both quantities. The dependence between the cure proportion, pi, and the
covariates can be modelled using different link functions;
1. the identity link, pi = zβ. The covariate effects are in units of the cure proportion.
2. the logistic link, log(pi/(1 − pi)) = zβ. Covariate effects are expressed as log odds of
cure.
3. the complementary log-log link, log(− log(pi)) = zβ.
The overall (all-cause) hazard is the sum of the background mortality rate and the excess
mortality rate associated with the cancer of interest
h(t; z) = h∗(t; z
′
) +
(1− pi(z))fu(t; z)
pi(z) + (1− pi(z))Su(t; z) (22)
where h∗(t; z
′
) is the expected mortality rate and fu(t; z) is the density function associated
with Su(t; z). The log-likelihood (equation 15) becomes
lnL =
N∑
i=1
di ln
(
h∗(ti; z
′
i) +
(1− pi(zi))fu(ti; zi)
pi(zi) + (1− pi(zi))Su(ti; zi)
)
+ln(pi(zi)+(1−pi(zi))Su(ti; zi)).
(23)
A mixture cure model with Weibull distribution and logistic link was used in paper I to
study temporal trends in survival of patients with acute myeloid leukaemia.
Non-mixture cure model
Another cure model that has been proposed within a relative survival setting is the non-
mixture cure model [39, 45], which estimates an asymptote for the survival function at
the cure proportion. The non-mixture cure model was first introduced to model tumour
recurrence [46, 47], but can also be used to model the statistical cure proportion. The
survival function for the non-mixture model can be written as
S(t; z) = S∗(t; z
′
)pi(z)Fy(t;z) = S∗(t; z
′
) exp(ln(pi(z))− ln(pi(z))Sy(t; z)), (24)
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where Fy(t; z) is a distribution function with Sy(t; z) its corresponding survival function, and
as for the mixture model, a Weibull distribution is often used. The overall hazard function
is written as
h(t; z) = h∗(t; z
′
)− ln(pi(z))fy(t; z). (25)
The non-mixture cure model can be expressed as a mixture cure model by rewriting equation
(24) as
S(t; z) = S∗(t; z
′
)
(
pi(z) + (1− pi(z))
(
pi(z)Fy(t;z) − pi(z)
1− pi(z)
))
(26)
and thus the survival distribution of the uncured can be estimated. The log-likelihood
function becomes
lnL =
N∑
i=1
di ln(h
∗(ti; z
′
i)− ln(pi(zi))fy(ti; zi)) + (ln(pi(zi))− ln(pi(zi))Sy(ti; zi)). (27)
As in the previous section, the covariates included for modelling the cure proportion and
the distribution function could be different, and the same link functions as described in the
previous section can be used for modelling of the cure proportion. If the function fy(t) in
equation (25) is not allowed to vary by covariates the non-mixture cure model is a propor-
tional excess hazards model. This is a difference between the mixture and non-mixture cure
models, since the former does not have a proportional excess hazards model for the whole
group as a special case. If a complementary log-log link is used in a non-mixture cure model
for which the function fy(t) do not vary by covariates (if proportional excess hazards can be
assumed) the covariate effects are expressed as log excess hazard ratios. The non-mixture
cure model can also be extended to use splines for modelling of the distribution function
Fy(t), which is done in paper II where the flexible parametric survival model is adapted to
estimate cure.
Interpreting temporal trends using cure models
Cure models give estimates of both the cure proportion and the survival distribution of the
uncured. By studying temporal trends in both these measures simultaneously, more can be
understood about changes in survival than by for example only studying the 5-year RSR. A
summary measure for the survival distribution of the uncured is usually presented together
with the cure proportion, and the most often used summary measure is the median survival
time of the uncured.
When studying temporal trends in cure and median survival time of uncured, the four
scenarios illustrated in Figure 2 can often be used to facilitate the interpretation. These sce-
narios are (a) increased cure proportion and median survival time of uncured, (b) increased
12
cure proportion but decreasing median survival time of uncured, (c) increased median sur-
vival time of uncured and unchanged cure proportion or (d) increased cure proportion but
unchanged median survival time of uncured. Even though these scenarios are a simplification
of reality, they can still be useful when interpreting temporal trends in the two quantities.
(a)
(b)
(c)
(d)Su
rv
iva
l o
f U
nc
ur
ed
Cure Fraction
Adapted from Verdeccia (1998)
Figure 2 – Hypothetical changes in the cure fraction and median survival time of uncured
between two calendar periods of diagnosis.
A general improvement of cancer patient survival might increase the chance of cure and
also prolong life for those uncured, this is one possible explanation for observing scenario
(a). When more patients are cured, those left in the uncured group are often those with
worse prognosis. The cure proportion will then be increasing and the median survival time
may decrease due to the selection of people to the ‘cured group’, this is seen as scenario
(b). If treatment and management of cancer is improving even though the improvement
does not lead to better possibilities of cure, scenario (c) can be observed. Another reason for
observing scenario (c) could be lead time bias. Since the cure proportion does not depend
on follow-up time it is not affected by lead time, and the cure proportion can therefore be
used when lead time is a concern. This is why we chose to present the cure proportion as
a complement to 5-year RSR in a study comparing survival between screen-detected and
symptomatic cervical cancer in Sweden [48]. Scenario (d) could be seen if a new diagnostic
procedure find patients with early stage disease that would never have been diagnosed if the
procedure was not introduced. The new cases belong to the ‘cured group’, thus the cure
proportion increase, but no change in the median survival time for the uncured is seen. In
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reality, many things will simultaneously have an impact on the survival, and interpreting
temporal trends always have to be done with care and all potential changes in diagnostic
procedures should be taken into account.
2.9 Period analysis
To predict the survival for recently diagnosed patients, that have not yet been followed long
enough to estimate their survival, a period approach to estimation has been suggested and
proven empirically superior to the cohort approach [49, 50, 51, 52]. In a period analysis,
only recently diagnosed patients contribute to the estimates of short term survival whereas
patients diagnosed further in the past still contribute to estimates of long term survival,
and therefore recent improvement in survival can be better captured. This set-up is made
possible by pre-specifying a period window, and only person-time experienced within the
period window contributes to the analysis. This is illustrated in figure 3, with a three year
period window.
Period of Interest
Start and Stop
at Risk Times
Standard Period
(0, 2)
(0, 4)
(0, 6)
(0, 3)
(0, 2)
(2, 4)
(5, 6)
(−, −)Subject 4
Subject 3
Subject 2
Subject 1
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
Year
Diagnosis
Death or Censoring
Figure 3 – Illustration of period analysis.
Subject number 1 is diagnosed within the period window and contributes follow-up time
for the first 2 years after diagnosis. Subjects 2 and 3 are diagnosed prior to the period window
and only contribute follow-up time to years 2-4 and 5-6, respectively. Subject number 4 is
diagnosed prior to the period window, but also exits the study before the start of the period
window and therefore does not contribute any follow-up time to the period analysis.
In survival analysis, a situation where all individuals are not followed from time 0 is
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referred to as left truncation or delayed entry. Left truncation is easily incorporated into the
likelihood by conditioning on being alive at the time point an individual enters the study.
The log likelihood for a period analysis in a relative survival setting becomes
lnL =
N∑
i=1
di ln[h
∗(ti; z
′
i) + λ(ti; zi)] + ln[R(ti; zi)]− ln[R(li; zi)], (28)
where li is the time of entry for individual i. A period analysis was performed in paper
IV to estimate the loss in expectation of life for recently diagnosed colon cancer patients in
Sweden.
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3 Aims of this thesis
The major objective of this PhD project was to develop and apply methods for presenting
cancer survival statistics that are relevant for epidemiologists, clinicians and patients. More
specifically:
• to extend the flexible parametric survival model to model the cure proportion among
cancer patients.
• to extend the flexible parametric survival model to estimate the loss in expectation of
life among cancer patients.
• to apply methods for population-based cancer patient survival to cancer registry data
with the joint aim of evaluating the new methodology, presenting the new methodology
to the broader research community, evaluating cancer care and gaining greater insights
into temporal trends in cancer patient survival.
• to develop user friendly software to enable application of the methods.
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4 Developed methods
4.1 Flexible parametric cure models
The cure models presented in section 2.8 require a parametric distribution to express either
Su(t) or Fy(t), and a Weibull distribution is often used. However, it has been shown that the
Weibull distribution, and other distributions, are not always flexible enough to capture the
shape of the underlying distribution [42, 53, 54]. More specifically, when the relative survival
function drops substantially within a short time period after diagnosis (i.e. the excess hazard
rate is initially very high) but later on reaches a plateau, the parametric distributions do not
always give a good fit to the data. This type of scenario is often observed among older age
groups, and is one reason why older patients have often been excluded from studies using
cure models, for example in the study by Lambert et al. [42]. Another problem occur when
the relative survival is high (survival of about 0.8 or above), for example among patients
with localised disease, since the cure models often do not converge in these scenarios. A lot
of alternative cure models have been suggested over the years, of which some are non- or
semi-parametric (e.g, [55, 56, 57, 58]) or use a Bayesian approach (e.g, [59, 60]) or a spline-
based approach (e.g, [61, 62, 63]). However, these approaches have not been developed in
a relative survival setting. To overcome the shortcomings of standard relative survival cure
models we adapted the flexible parametric relative survival model to estimate cure. This
was published in paper II, together with an evaluation of how well the model performs in a
situation where a mixture or non-mixture cure model with Weibull distribution did not give
a good fit. A summary of paper II is given in section 6.2, but the method development is
described here.
To estimate the cure proportion from the flexible parametric relative survival model we
used the fact that when cure is reached the excess hazard rate is zero, and the cumulative
excess hazard will therefore be constant after this point in time. By forcing the log cumulative
excess hazard in the flexible parametric survival model to not only be linear after the last
knot, but also to have zero slope, we impose a cure point and enable estimation of the cure
proportion. This is done by manipulating the splines in the flexible parametric survival
model. All spline functions except the linear, v1(x) = x, are 0 before the first knot, so by
imposing constraints on the parameter, γ01, associated with this linear term it is possible
to determine the slope of the spline before the first knot. To enforce cure, this has to be
done after the last knot instead. By treating the knots in reversed order, all spline functions
except the linear take the value 0 after the last knot instead of before the first. For lack of
a better word, I refer to these new manipulated splines as “backwards” splines. The spline
17
basis functions, vp(x), in the backwards spline are defined as
vp(x) =
x, for p = 1(kK−p+1 − x)3+ − λp(kK − x)3+ − (1− λp)(k1 − x)3+, for p = 2, ..., K − 1 (29)
where λp =
kK−p+1−k1
kK−k1 . By using this backward spline in the flexible parametric survival
model and constraining γ01 to 0, the log cumulative excess hazard, and therefore also the
cumulative excess hazard, has 0 slope after the last knot and a cure point is imposed. The
relative survival function for the flexible parametric survival model, with splines calculated
backwards and with restriction for the linear spline parameter, from now on called the flexible
parametric cure model, is defined as
R(t) = exp(− exp(γ00 + 0× v1(x) + γ02v2(x) + ...+ γ0K−1vK−1(x))), (30)
which can be written as
R(t) = piexp(γ02v2(x)+...+γ0K−1vK−1(x)), (31)
where pi = exp(− exp(γ00)). When comparing to a non-mixture model we can see that
the flexible parametric cure model is a special case of a non-mixture cure model with pi =
exp(− exp(γ00)), and Fy(t) = exp(γ02v2(x) + ... + γ0K−1vK−1(x)). Fy(t) is a distribution
function as long as the excess mortality is not negative, which is seen very rarely. As this
is a non-mixture model, the flexible parametric cure model is a proportional excess hazards
model, as long as no time-dependent effects are modelled.
When incorporating covariates,
R(t; z) = exp(− exp(γ00 + zβ))(exp(γ02v2(x)+...+γ0K−1vK−1(x)+
∑D
i=1 s(x;γi)zi)) (32)
we see that the constant parameters, γ00 and β, are used to model the cure proportion and the
time-dependent parameters are used to model the distribution function Fy(t). The constraint
of a zero effect for the linear spline term has to be incorporated for each time-dependent
effect included in the model.
The constant parameter, γ00, in equation (32) gives the log cumulative excess hazard at
the time point of the last knot for the reference group and can be used to predict cure, since
all other spline variables are 0 at the last knot. It is usually preferable to orthogonalise the
spline variables, to avoid collinearity between the spline functions, which results in them not
being zero from the point of the last knot. If orthogonalised splines are used, the same model
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is being fitted, but the parameters take different values, and cure can then not be predicted
by a direct transformation of the constant parameters. We therefore chose to center the
orthogonalised spline variables around the value they take at the last knot, which enables
direct predictions of cure from the constant parameters. Not only the cure proportion, but
also the survival of uncured can be estimated from the flexible parametric cure model in
the same way as for the non-mixture cure model, as seen in equation (26). The median
survival time of uncured, or any other percentile, can be estimated using a Newton-Raphson
algorithm.
We have adapted the Stata package for flexible parametric survival models (stpm2) [5],
to include the flexible parametric cure model as a special case as well as post estimation
commands to predict the cure proportion and the survival of the uncured. The updated
Stata package is described in a paper that is not part of this thesis, but included as an
appendix for completeness [64].
4.2 Life expectancy and loss in expectation of life
A useful summary measure for survival data is the life expectancy (LE), or mean survival
time, which can be obtained by calculating the area under the survival curve. For cancer
patients, the life expectancy from the date of the cancer diagnosis gives an estimate of the
number of years a patient lives on average after they are diagnosed with cancer [65]. This is
estimated by integrating the all-cause survival function
LE(z) =
∫ ∞
0
S(u; z)du, (33)
where t = 0 is the time of diagnosis. Note that it is the all-cause survival, S(t) that is of
interest, not the net survival. Integration should in theory be done up to ∞, but in practice
a time point, tmax, is used where the survival function is assumed to have reached zero (i.e.
all patients are assumed dead).
The loss in expectation of life (LEL) due to cancer is the difference between the expecta-
tion of life the patients would have had if they had not been diagnosed with cancer, estimated
using population mortality rates for the general population, and the observed expectation of
life among the cancer patients.
LEL(z) =
∫ tmax
0
S∗(u; z
′
)du−
∫ tmax
0
S(u; z)du, (34)
where t = 0 is the time of diagnosis and tmax is a point in time where both the expected and
observed survival are assumed to have reached zero. Another measure is the proportion of
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expected life lost (PELL), obtained by dividing the difference by the expectation of life,
PELL(z) =
(∫ tmax
0
S∗(u; z
′
)du− ∫ tmax
0
S(u; z)du
)
(∫ tmax
0
S∗(u; z′)du
) . (35)
The loss in expectation of life, or the proportion of expected life lost, can be a useful measure
for quantifying the cancer burden in the society or for an individual and for quantifying
differences in survival between groups [65, 66].
The estimation of life expectancy generally requires extrapolation of the survival function
beyond the available data, since the cohort of interest is in principle never followed up
until the time point, tmax, when the survival function reaches zero. To estimate the loss
in expectation of life, both the expected (general-population) survival and the observed all-
cause survival (of the cancer patients) have to be extrapolated.
The expected survival can be extrapolated by making assumptions about the future mor-
tality in the general population. The all-cause survival among the cancer patients can be
extrapolated by assuming a parametric distribution, but it is difficult to find a statistical
distribution that captures the underlying shape of the survival function, and even though
a parametric distribution may fit well to the observed follow-up it may extrapolate poorly.
Hakama and Hakulinen [67] suggested extrapolating the relative survival, and use the in-
terrelationship between observed, expected and relative survival to obtain the extrapolated
all-cause survival function. By breaking down the all-cause survival into two component
parts, the expected survival and the relative survival, one can make assumptions for ex-
trapolation of these functions independently. For most types of cancer the excess mortality
is low after some years from diagnosis, so the expected mortality dominates for long-term
follow-up, and the extrapolation therefore mostly depends on the extrapolation of the ex-
pected survival. Hakama and Hakulinen estimated loss in expectation of life using grouped
data (life tables of relative survival) and suggested to extrapolate the relative survival by
assuming statistical cure or by assuming that the excess mortality had stabilised to a con-
stant. Other approaches that use background mortality have been suggested, of which some
assume that background mortality alone can be used beyond the available follow-up [65, 68],
and other extrapolate based on a linear regression model on the logit of relative survival or
quality-adjusted survival [69, 70]. Nelson et. al use the observed data to estimate rates as
a function of age and use that for extrapolation [71] beyond the available follow-up. Others
have used parametric distributions to extrapolate the survival function [72, 73, 74, 75].
A similar measure, more commonly reported, is the years of life lost. Years of life lost is
estimated as the difference between the age at death and the life expectancy of each patient
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or a pre-specified cut-off age [66, 76, 77, 78]. However, this approach relies on accurate cause
of death information to identify individuals in the population who died due to cancer. Since
the approach only includes patients who have died, and specifically only those who die of
their cancer, irrespective of when they were diagnosed, it can not be used for a specific cohort
of patients. In addition, if a cut-off is used, any differences between groups that occur after
the cut-off age are ignored. Life expectancy and the loss in expectation of life do not suffer
from the same limitations.
In paper III, we demonstrate how the loss in expectation of life can be estimated by
the use of a flexible parametric survival model. A flexible parametric survival model for
the cumulative all-cause mortality, H(t), can be used for extrapolating beyond the available
follow-up, but the fit is not always good. Instead, similarly to Hakama and Hakulinen, we
suggest to model the cumulative excess mortality part using a flexible parametric survival
model. Three possible approaches for the extrapolation from a flexible parametric survival
model for relative survival are:
1. Linear trend. Since restricted cubic splines are linear beyond the boundary knots, the
flexible parametric survival model gives a linear log cumulative excess hazard beyond
the last knot, or equivalently behaves like a Weibull distributed excess hazard in the
tail. The linear trend is mainly based on the observed trend towards the end of follow-
up.
2. Cure. Assuming statistical cure beyond the last boundary knot, by the use of a flexible
parametric cure model presented in section 4.1, thus after the cure point we can use
the expected survival alone when extrapolating.
3. Constant excess hazard. Assuming a constant excess hazard beyond the last boundary
knot. To incorporate an assumption of constant excess hazard a similar approach as
for the flexible parametric cure model is used. The spline variables are again calculated
“backwards” and the parameter for the linear spline variable, γ01, is set to 1. This gives
an excess hazard that behaves like an exponential distribution in the tail. For this
approach the smoothness of the splines can be relaxed slightly, which is described in
section 4.3.
Based on the model the extrapolated relative survival can be estimated. When the full
(extrapolated) relative survival function has been estimated the full (extrapolated) all-cause
survival function can be estimated by multiplying the relative survival by the (extrapolated)
expected survival function. The loss in expectation of life is then estimated as
LEL(z) =
∫ tmax
0
S∗(u; z
′
)du−
∫ tmax
0
R(u; z)S∗(u; z
′
)du. (36)
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The post estimation command for the Stata package stpm2 (package for flexible paramet-
ric survival models in Stata) has been extended to enable estimation of the life expectancy
and loss in expectation of life. In the Stata package, the integrals are obtained numerically
using the Gaussian quadrature rule [79] and the variance of the loss in expectation of life is
obtained using the delta method [80].
4.3 Making splines more flexible
Restricted cubic splines are by design very smooth, and that is partly why they are so
popular. In most applications of flexible parametric survival models the smoothness of the
restricted cubic splines is an advantage. However, when one wants to change the behaviour
of the splines in the tail of the distribution, as in the flexible parametric cure model or
to impose a constant excess hazard after a certain point (which has been suggested for
estimation of loss in expectation of life), the smoothness of the splines might introduce
incorrect shapes of the cumulative hazard even prior to the point where the restriction is
imposed. This primarily happens when the imposed constraint forces the log cumulative
(excess) hazard function to change from a concave to a convex function or vice versa. Since
the log cumulative excess hazard function is usually a concave function the problem will
arise when a constant excess hazard is imposed after the last knot, but not so often when
imposing a cure point. This is illustrated graphically in figure 4, where the log cumulative
excess hazard function from a model without constraint, a model with constant excess hazard
after 8 years post diagnosis and a model with a cure point at 8 years post diagnosis is plotted
against log time, together with their corresponding cumulative excess hazard, excess hazard
and relative survival functions. For all three models, the last knot was positioned at 8
years after diagnosis, and this point is shown in the graphs as a vertical line. In the flexible
parametric relative survival model the log cumulative excess hazard is modelled as a function
of log time using splines, which is why we chose to show the log cumulative excess hazard
against log time even though it would not usually be the scale of interest.
To overcome this potential problem, I relaxed the conditions of the restricted cubic spline
by not requiring a continuous first and second derivative at the last knot. To construct a
restricted cubic spline without continuous first and second derivative at the last knot I started
with constructing a restricted cubic spline without continuous first and second derivative at
the first knot. Firstly, a general cubic spline with K knots is specified as
s(x;γ) = γ01x+ γ02x
2 + γ03x
3 +
K−1∑
p=2
(
γp(x− kp)3+
)
+ γ1(x− k1)3+ + γK(x− kK)3+, (37)
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Figure 4 – Log cumulative excess hazard, cumulative excess hazard, excess hazard and relative
survival functions from a standard flexible parametric survival model, a model with constant
excess hazard after 8 years and a model with a cure point at 8 years.
where kp refers to the p
th knot [6]. A cubic spline (with K knots) without the constraint of
continuous second derivative at the first knot is written as
s(x;γ) = γ01x+γ02x
2+γ03x
3+
K−1∑
p=2
(
γp(x−kp)3+
)
+γ1(x−k1)3++γK(x−kK)3++γextra(x−k1)2+.
(38)
So we now have one extra parameter γextra and the extra spline variable corresponding to
this parameter (x − k1)2. A cubic spline (with K knots) without constraint of continuous
first or second derivative at the first knot is written as
s(x;γ) =γ01x+ γ02x
2 + γ03x
3 +
K−1∑
p=2
(
γp(x− kp)3+
)
+ γ1(x− k1)3+ + γK(x− kK)3++
γextra1(x− k1)2+ + γextra2(x− k1)+.
(39)
So we now have two extra parameters γextra1 and γextra2 and the extra spline variables
corresponding to these parameters are (x − k1)2 and (x − k1). Restricted cubic splines are
forced to be linear before the first knot and after the last knot. To impose linearity before
the first knot we need to set γ02 = γ03 = 0. To impose linearity after the last knot we use
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the fact that s′′(x) = s′′′(x) = 0 for linear functions. So for x > kK
s′(x;γ) = γ01+3
K−1∑
p=2
(
γp(x−kp)2
)
+3γ1(x−k1)2+3γK(x−kK)2+2γextra1(x−k1)+γextra2 (40)
s′′(x;γ) = 6
K−1∑
p=2
(
γp(x− kp)
)
+ 6γ1(x− k1) + 6γK(x− kK)2 + 2γextra1 (41)
s′′′(x;γ) = 6
K−1∑
p=2
γp + 6γ1 + 6γK (42)
Setting s′′(x) = s′′′(x) = 0 gives:
s′′′(x;γ) = 0 =⇒ γK = −
K−1∑
p=2
γp − γ1 (43)
s′′(x;γ) = 0 =⇒ γ1(x− k1) = −
K−1∑
p=2
(
γp(x− kp)
)− γK(x− kK)− γextra1/3 (44)
substituting γK =⇒
γ1(x− k1) = −
K−1∑
p=2
(
γp(x− kp)
)
+
K−1∑
p=2
(
γp(x− kK)
)
+ γ1(x− kK)− γextra1/3
=⇒ γ1 = −
K∑
p=2
−1γpλp − cγextra1
=⇒ γK = −
K∑
p=2
−1(γp(1− λp))+ cγextra1
(45)
where λp = (kK − kp)/(kK − k1) and c = 1/(3(kK − k1)). A restricted cubic spline with
relaxed smoothness at the first knot is therefore expressed as
s(x;γ) =γ01x+
K−1∑
p=2
(
γp
(
(x− kp)3+ − λp(x− k1)3+ − (1− λp)(x− kK)3+
) )
+
γextra1
(
(x− k1)2+ − c(x− k1)3+ + c(x− kK)3+
)
+ γextra2(x− k1)+,
(46)
where λp = (kK − kp)/(kK − k1), c = 1/(3(kK − k1)) and kp refers to the pth knot.
To construct a cubic spline with relaxed smoothness at the last knot, we want to calculate
equation (46) backwards, i.e. treating the knots in reversed order, so that all variables except
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the linear term are 0 after the last knot instead of before the first knot. This is done in the
same way as for standard restricted cubic splines, as explained in section 4.1, but with the
extra variables also calculated in the reversed way. Backwards restricted cubic splines (with
K knots) without the constraints of continuous first or second derivative at the last knot is
written as
s(x;γ) =γ01x+
K−1∑
p=2
(
γp
(
(kK−p+1 − x)3+ − λp(kK − x)3+ − (1− λp)(k1 − x)3+
) )
+
γextra1
(
(kK − x)2+ − c(kK − x)3+ + c(k1 − x)3+
)
+ γextra2(kK − x)+,
(47)
where λp = (kK−p+1 − k1)/(kK − k1) and c = 1/(3(kK − k1)). A difference between the
new, more flexible, restricted cubic splines and standard restricted cubic splines is that the
forward and backwards spline will not give the same model with the new splines, since the
relaxed constraints are in different places.
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Figure 5 – Log cumulative excess hazard, cumulative excess hazard, excess hazard and relative
survival functions from a standard flexible parametric survival model, a model with constant
excess hazard after 8 years and a model with a cure point at 8 years. The two latter are
modelled with splines allowed to have non-continuous first and second derivative at the last
knot.
Results using the new more flexible spline is seen in figure 5, where the models with
a constant excess hazard and cure are refitted using the more flexible splines. The three
models now agree very well up until the position of the last knot. The hazard function is the
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Figure 6 – Log cumulative excess hazard, cumulative excess hazard, excess hazard and relative
survival functions from a standard flexible parametric survival model, a model with constant
excess hazard after 8 years and a model with a cure point at 8 years. The two latter are
modelled with splines allowed to have non-continuous second derivative at the last knot.
derivative of the cumulative hazard function and, due to the relaxation of the smoothness,
the derivative of the cumulative hazard function is not defined at the position of the last
knot, and therefore the hazard function can jump in the way seen in figure 5. In this example
a constant excess hazard is not a reasonable assumption, which makes this a good example
for illustrating the potential problem with imposing constraints after the last knot, and the
jump would be smaller if a constant excess hazard was more reasonable. However, we have
not found a dataset where it seems plausible to assume a constant excess hazard, and where
the new spline fit well. Therefore, I would not recommend the use of these splines for this
purpose without thorough sensitivity analyses. Even so, the more flexible splines were used
in paper III to fit models that assumed a constant excess hazard after the last knot, since
they at least do not impose implausible shapes of the cumulative excess hazard function
prior to the last knot.
Instead of relaxing both the first and second derivative at the last knot, splines with only
non-continuous second derivative at the last knots can be used. The exact description will
not be given here, but the construction of these splines is similar to the description above.
These splines could potentially be advantageous to use within the flexible parametric cure
model, but they are not smooth enough to overcome the problem of an inflection point when
assuming a constant excess hazard, as seen in figure 6.
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5 Materials
5.1 The Swedish Cancer Registry
The Swedish Cancer Registry was established in 1958, and all health care providers and
pathologists are obliged by law to notify the registry about all new cases of cancer. Since
the 1980’s the registration and coding is done at six regional registries located in each of
the six Swedish health care regions. Information is collected by the regional registries on
patient characteristics such as age and sex, as well as tumour characteristics such as stage and
histopathology. The cancer registries also obtain follow-up information on date and cause of
death as well as date of emigrations. This is done by linking the data to other registries by
the use of the ten-digit ID number allocated to all residents in Sweden. For most diagnosed
cancers the regional registry will receive two independent reports, one from the pathologist
and one from the clinician. The regional cancer registries annually supply data to the
national Swedish Cancer Registry, and the completeness of the register is above 96% [81].
The national cancer register include less detailed information than the regional registries,
and stage at diagnosis was not reported to the national register until 2004. Data from the
Swedish cancer register was used in studies I, III and IV. Paper I includes diagnoses of acute
myeloid leukaemia (AML), paper III diagnoses of breast cancer, colon cancer, malignant
melanoma as well as bladder cancer and paper IV includes diagnoses of colon cancer. More
detailed information on the data used in each paper is given in the brief summary of each
paper in section 6.
5.2 The Finnish Cancer Registry
The Finnish Cancer Registry started in 1953, and cancer reporting has been compulsory since
1961. The register includes data about the patient as well as information about the tumour,
and the completeness of registration is over 99% [82]. The underlying cause of death is
recorded for all cases, using death certificate information from Statistics Finland by linkage
through the ten-digit ID number allocated to all residents. Death certificate information
from Statistics Finland is also used to add cancers notified on death certificates that have
not previously been recorded in the cancer register, i.e. death certificate only (DCO) cases.
This is a difference between the Finnish and Swedish cancer registries since the latter does
not include DCO cases. The Finnish Cancer Registry is also an active research institute
that performs statistical and epidemiological cancer research. Data on colon cancer in the
Finnish cancer register was used in paper II, more detailed information is given in section 6.
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6 Summary of papers
6.1 Paper I
Background
Acute myeloid leukaemia (AML) is an aggressive disease and rapidly fatal if left untreated.
Curative treatment is now available which has led to improved patient survival. Large
age-dependent differences in AML patient survival and greater improvement over time for
younger patients have been shown in Sweden [83]. In that study AML patient survival was
presented as 1- and 5-year RSR for different age groups and calendar periods. In this study
we reanalysed the data using cure models to gain further insights into changes observed in
AML patient survival over time and how these changes vary between different age groups.
Material
We identified all AML diagnoses, International Classification of Diseases revision 7 (ICD-7)
codes 2050, 2059, 2060, 2069 and recorded as malignant, in the Swedish Cancer Registry
between 1973–2001. If the same individual had more than one AML diagnosed within this
time period, only the first was included. Incidental autopsy findings, in total 330 cases, were
excluded. Patients 18 years or younger and 81 years or older at the time of diagnosis were
excluded, which led to the exclusion of 1 604 patients. AML is not common among children
and therefore we chose to restrict to adult patients, and the reason to exclude patients older
than 80 was that the cure models tend to be less reliable for older age groups, as described
in section 4.1. After also excluding 35 patients with reported date of death or emigration
before the date of diagnosis, the study population consisted of 6 439 patients. Patients were
followed until death or censored 10 years after diagnosis, at date of emigration or December
31 2006, whichever occurred first.
Methods
A mixture cure model (described in section 2.8) was used with a Weibull distribution for the
survival function of the uncured and a logistic link for the cure proportion. The variables of
interest were age at diagnosis and year of diagnosis. We chose to include age as a categorical
variable, with the same categorisation as in the previous study [83] (19-40, 41-60, 61-70, 80
years and above). In the previous study calendar period was also included as a categorical
variable, but in this study we chose to model calendar year as a continuous variable using
restricted cubic splines (with four knots) to gain further insights into the temporal trends in
AML patient survival. The cure proportion as well as both Weibull parameters were allowed
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to vary by both age group and calendar year and an interaction between age group and
calendar year was included. The analysis was carried out using the command strsmix [53]
in Stata (Statacorp, College Station, TX).
Results
Both the cure proportion and the median survival time of uncured were low at the start of
the study period (figure 7) for all age groups. But a dramatic improvement is seen for the
youngest age group, with the cure proportion increasing from 4% (95% CI 2-10) in 1975 to
68% (95% CI 56-77) in 2000 and the median survival time of the uncured increasing from
0.43 years (95% CI 0.32-0.58) in 1975 to 1.08 years (95% CI 0.90-1.31) in 1990 and then
decreased to 0.74 years (95% CI 0.43-1.26) in 2000. For the second age group (age 41-60
years at diagnosis) the cure proportion started to increase during the mid 1980s and was
32% (95% CI 25-39) in 2000 and the median survival time of the uncured increased to about
1 year in the mid 1990s and then decreased slightly. There were small improvements seen
in the cure proportion of the third age group (61-70 years) and the cure proportion in 2000
was 8% (95% CI 3-21), while the median survival time of the uncured increased to about
0.7 years. Only small improvement in the median survival time of the uncured was seen for
those aged 71-80 years at diagnosis, and no improvement in the cure proportion.
Sensitivity analysis
Whenever cure models are used, the assumption of an existing cure point should always be
assessed. This was also performed within this study, but the results were not presented in
detail in the paper. A mixture cure model was fitted to each age group, separately for each
of the calendar periods 1973-1981, 1982-1990, 1991-2001. The relative survival estimated
from the cure models was compared to empirical life table estimates of relative survival, to
compare the fit as well as to evaluate the cure assumption. The results can be seen in figure
8. The empirical relative survival estimates reach a plateau, indicating statistical cure, and
the relative survival estimated from the cure models closely follow the life table estimates of
relative survival.
Conclusion
We saw large improvement in the cure proportion among younger ages, whereas improvement
in the oldest ages is mainly within the survival of the uncured. The improvement in the cure
proportion was seen earlier in the younger age groups than in older patients which probably
can be explained by the fact that treatment with curative intent started earlier in younger
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Figure 7 – Temporal trends in cure proportion and median survival time (in years) of uncured
for patients diagnosed with AML in Sweden 1973-2001, presented by age group and with 95%
confidence intervals.
patients and was later on given to an increasing proportion of elderly patients. The median
survival time of the uncured decreased or was stable during the last ten years in all age groups.
This could be due to better selection of curable patients leaving poor risk patients to mainly
palliative care. Another explanation might be the highly toxic treatment, a patient treated
with curative intent has a good chance of being cured, but if the treatment is unsuccessful it
might shorten his or her life. Taken together, the information achieved by the use of a cure
model improved the understanding of temporal trends in AML patient survival.
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6.2 Paper II
Background
Cure models can be a valuable tool to gain insights in cancer patient survival, how it changes
over time or differs between groups. In population-based studies parametric cure models, as
described in section 2.8, are popular since they can easily be fitted within a relative survival
framework. A disadvantage of standard parametric cure models is that the distributional
assumption does not always give a good fit to the data. In this study we extended the flexible
parametric survival model to enable cure modelling with the use of splines. The new method
is described in section 4.1, and the evaluation of the method is presented in this section.
Material
In a study by Lambert et al. [42] a mixture cure model with a Weibull distribution was used
to study temporal trends in cancer of the colon and rectum in Finland. In that study patients
aged 80 and older at diagnosis where excluded due to a poor fit of the cure model. In this
study we reexamined the data on colon cancer, including patients aged 80 and older, using
the flexible parametric cure model to compare the fit of the new model with the mixture and
non-mixture cure model.
Methods
In the study by Lambert et al. a mixture cure model with Weibull distribution was used,
including the variables year of diagnosis (modelled continuously with splines) and age at
diagnosis (in categories less than 50, 50-59, 60-69 and 70-79) as well as an interaction between
age group and year. All three model parameters, the cure proportion and the two Weibull
parameters, were allowed to vary by covariates. In this study, since the flexible parametric
cure model is a special case of a non-mixture cure model, we compared the flexible parametric
cure model to a non-mixture cure model instead of a mixture cure model, but the two
parametric models give very similar results. A Weibull non-mixture cure model and a flexible
parametric cure model were fitted including the same covariates as in the previous study,
but also including the age group 80 and older. Estimated cure proportions and median
survival times of uncured were compared. The fit of the cure models were also compared to
empirical life table estimates of relative survival, separately for each age group and calendar
periods 1953-1964, 1965-1974, 1975-1984, 1985-1994 and 1995-2003. To investigate how
the flexible parametric cure model performs in a situation where survival is high a subset
analysis, restricted to localised cancer only, was performed. The fit of the non-mixture
32
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
iv
e 
Su
rv
iva
l
0 2 4 6 8 10
Years from Diagnosis
Age group 60−69 Period 1975−1984
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
iv
e 
Su
rv
iva
l
0 2 4 6 8 10
Years from Diagnosis
Age group 80+ Period 1975−1984
Non−mixture cure model Flexible parametric cure model
Life table estimates 95% CI
Figure 9 – Predicted survival and cure proportions (%) from non-mixture models and flexible
parametric cure models, compared to life table estimates of relative survival.
and flexible parametric cure model were again compared to empirical life table estimates of
relative survival, separately for each age group and calendar period.
Results
Figure 9 shows the predicted relative survival and cure proportions from non-mixture cure
models and flexible parametric cure models fitted to the age groups 60-69 and 80 and older
during calendar period 1975-1984, together with empirical life table estimates of relative
survival. The predicted survival and cure proportions from the two cure models agree well
for age group 60-69, and also correspond well with the life table estimates. For the oldest
age group on the other hand, the two cure models do not agree as well, and the flexible
parametric cure model follows the empirical life table estimates much more closely, giving a
much better fit to the data. The difference between the two cure models is also seen in figure
10, where the cure proportion (together with 95 % CI), from models where calendar year
is modelled using splines, is plotted for the same two age groups. The cure proportions are
similar for the age group 60-69, but for the oldest age group where the parametric cure model
has been shown to overestimate cure, the flexible parametric cure model gives lower estimates
of cure. When restricting the data to localised cancer only, the Weibull non-mixture model
did not converge for all combinations of age and calendar period. However, the flexible
33
0.0
0.2
0.4
0.6
Cu
re
 P
ro
po
rti
on
1950 1960 1970 1980 1990 2000
Year of Diagnosis
Aged 60−69
0.0
0.2
0.4
0.6
Cu
re
 P
ro
po
rti
on
1950 1960 1970 1980 1990 2000
Year of Diagnosis
Aged 80+
Flexible cure model Non−mixture cure model
Figure 10 – Predicted cure proportions (%) with 95% CI from a Weibull non-mixture cure
model and a flexible parametric cure model.
parametric cure model gave sensible estimates (when compared to life table estimates of
relative survival) in all scenarios, and always converged.
Conclusion
The flexible parametric cure model enables estimation of cure when parametric cure models
are not flexible enough, which enables for example, inclusion of older age groups. The stpm2
Stata package for estimation of flexible parametric survival models [5] has been updated to
enable the use of the proposed method [64].
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6.3 Paper III
Background
Life expectancy and loss in expectation of life can be used to address a wide range of research
questions of public health interest pertaining to the prognosis of cancer patients, but due to
the need for extrapolation of the survival curve they are rarely reported. In this study we
showed that the flexible parametric survival model can reliably extrapolate relative survival.
By using the relationship between all-cause, relative and expected survival, the extrapolated
all-cause survival can also be reliably estimated. This approach can then be used to estimate
life expectancy and loss in expectation of life for cancer patients. The theory is described in
section 4.2, and the evaluation of the extrapolation is presented in this section.
Material and methods
Data on colon cancer, breast cancer, malignant melanoma and bladder cancer diagnosed in
Sweden 1961–1970 were used to evaluate how well the flexible parametric survival model
extrapolates survival. The observed mean survival time based on Kaplan-Meier estimates
(K-M) [84] of the available 40 years of follow-up was estimated and compared to mean
survival times estimated from extrapolated survival functions where follow-up was restricted
to 10 years for the analysis and extrapolated to 40 years. This was done separately for each
cancer site and four age groups (50-59, 60-69, 70-79 and 80 years and above). Extrapolation
was performed based on 5 different models:
1. extrapolating from a flexible parametric survival model for all-cause survival,
2. extrapolating from a flexible parametric survival model for relative survival,
3. extrapolating from a flexible parametric cure model for relative survival,
4. extrapolating from a flexible parametric survival model assuming constant excess haz-
ard from the point of the last knot,
5. extrapolating from a model assuming that the excess hazard follows a Weibull distri-
bution.
For more information about the different extrapolation approaches see section 4.2.
Results
The extrapolated relative survival gives a good estimate of the mean survival time in all age
groups and all of the four cancer sites (table 1), and performs much better than extrapola-
tion of all-cause survival. For colon cancer and melanoma, cancer sites often seen to reach
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Figure 11 – Observed Kaplan-Meier survival function for colon cancer together with the
extrapolated survival from a flexible parametric relative survival model and a flexible parametric
cure model.
statistical cure, the extrapolation assuming cure gives good estimates of the mean survival
time. Assuming cure does not give good estimates of the mean survival time for bladder
cancer or breast cancer, which is not surprising since cure is not a reasonable assumption
for these cancer sites. A Weibull distributed excess hazard or a constant excess hazard after
the last knot does not yield as good estimates of the mean survival time as the extrapolation
of the linear trend from the flexible parametric relative survival model. The mean survival
time from the extrapolation of the linear trend are in general very close to the observed
mean survival time, most differences are less than 0.5 years. The largest differences are seen
for the youngest age group, the group requiring extrapolation over a long period of time.
The observed K-M survival function for colon cancer is shown in figure 11 together with the
extrapolated survival from a flexible parametric relative survival model as well as a flexible
parametric cure model. The three curves agree very well, showing that the extrapolated
survival mimics the true observed survival among the cancer patients.
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Table 1 – Mean observed survival time (in years) along with the difference between the observed
and predicted mean survival times from 5 different extrapolation approaches, by cancer site
and age group, diagnosis in Sweden 1961-1970.
Colon cancer Age group
50-59 60-69 70-79 80+
Mean observed survival (years) 10.4 6.32 3.54 1.79
Difference:
All-cause extrapolated 2.96 2.13 0.71 0.004
Relative survival extrapolated -0.43 -0.23 -0.20 -0.24
Relative survival, cure 0.10 0.07 -0.13 -0.24
Relative survival, constant excess -3.03 -1.12 -0.40 -0.26
Relative survival, Weibull distribution -2.17 -0.95 -0.56 -0.43
Breast cancer Age group
50-59 60-69 70-79 80+
Mean observed survival (years) 14.0 10.0 6.23 3.05
Difference:
All-cause extrapolated 1.87 1.50 0.34 0.26
Relative survival extrapolated -0.63 -0.26 -0.05 0.18
Relative survival, cure 1.54 0.88 0.30 0.25
Relative survival, constant excess -2.66 -0.86 -0.16 0.17
Relative survival, Weibull distribution -1.97 -0.63 -0.10 -0.15
Melanoma Age group
50-59 60-69 70-79 80+
Mean observed survival (years) 15.9 10.4 5.50 3.22
Difference:
All-cause extrapolated 3.52 4.60 0.43 0.17
Relative survival extrapolated -0.95 -0.14 -0.04 -0.05
Relative survival, cure -0.12 -0.12 0.21 -0.04
Relative survival, constant excess -3.52 -1.34 -0.24 -0.06
Relative survival, Weibull distribution -2.61 -1.13 -0.23 -0.04
Bladder cancer Age group
50-59 60-69 70-79 80+
Mean observed survival (years) 13.8 7.94 4.54 2.28
Difference:
All-cause extrapolated 4.71 1.86 0.39 -0.12
Relative survival extrapolated 0.35 0.05 -0.10 -0.24
Relative survival, cure 1.26 0.58 0.06 -0.20
Relative survival, constant excess -1.62 -0.63 -0.26 -0.26
Relative survival, Weibull distribution -0.67 -0.43 -0.30 -0.34
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Conclusion
A relative survival approach is useful for extrapolating survival of cancer patients, and the
flexible parametric survival model for relative survival can be used to obtain reliable estimates
of the mean survival time. This enables estimation of the loss in expectation of life for
cancer patients, a measure that has not yet been widely used. The Stata command for
flexible parametric survival models stpm2 [5] has been extended to enable estimation of life
expectancy and loss in expectation of life.
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6.4 Paper IV
Background
In this study we demonstrated how estimation of loss in expectation of life can be used to
address a wide range of research questions concerning the prognosis of cancer patients, using
the methods developed in paper III. This is illustrated by investigating life expectancy and
loss in expectation of life after a diagnosis of colon cancer, how this changes over calendar
time as well as from time since diagnosis, and by quantifying the survival difference between
males and females.
Material
A total of 155 851 cases of colon cancer (ICD7 153) were identified in the Swedish Cancer
Register during the years 1961–2011, and after restricting to colon adenocarcinoma 135 702
cases were left. Individuals with multiple records of primary colon adenocarcinomas were
only included with their first recorded diagnosis which excluded 3 677 diagnoses. We further
excluded diagnoses that were detected incidentally at autopsy (4 644 cases), individuals aged
less than 20 at diagnosis (38 cases) or if the date of diagnosis was recorded to be after the
date of death (39 cases), which left a total of 127 304 patients in the cohort. All patients were
followed-up until death or censored at the date of first emigration after diagnosis, 2012-12-31
or 15 years after diagnosis, whichever came first.
Methods
Life expectancy and loss in expectation of life were estimated from a flexible parametric
relative survival model as described in section 4.2. Sex, age at diagnosis and year of diagnosis
were included in the model along with two-way interactions between them. Age and year
were both modelled continuously and non-linearly using restricted cubic splines, with only
the linear term included for interactions. Following the results in paper III we performed
the extrapolation based on a flexible parametric (relative) survival model without imposing
constraints of cure or constant excess hazard, even though a cure model could give a good
fit here. To obtain estimates for recently diagnosed patients a separate model including sex
and age was fitted using a period analysis approach (see section 2.9) with the period window
set to 2007-01-01 – 2012-12-31. Based on the results from the period analysis, the number
of life years potentially gained if colon cancer survival among males could be brought to the
same level as for females was estimated. This was performed by applying the female cancer
mortality rates to males (but keeping the male background mortality rates) and calculating
the total amount of life years lost for all patients in 2011 if males had the same colon cancer
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survival as females and contrasting this to the total amount of life years lost for all patients in
2011 given the survival differences between males and females. All analyses were performed
using the stpm2 command in Stata (Statacorp, College Station, TX, USA).
Results
The life expectancy for colon cancer patients in Sweden has increased over time (figure 12),
but the increase approximately mimics the increase observed in the general population and
therefore the loss in expectation of life has only had a modest decrease. As expected, the life
expectancy differs greatly by age, with longer life expectancy for younger patients. But since
younger patients also have more years to lose, due to a long life expectancy if cancer-free,
they on average lose more years due to cancer compared to older colon cancer patients. This
gives a complement to the often reported 5-year RSR, since the 5-year RSR is very similar
across age for colon cancer patients diagnosed in Sweden during the last 20 years. Female
colon cancer patients have a better life expectancy than males, but still have a greater loss
in expectation of life, due to higher life expectancy in the general population among females
compared to males.
The conditional loss in expectation of life decreased with follow-up time, especially during
the first years after diagnosis, as seen in figure 13, and the pattern was similar for males
and females and across calendar years. From a patient’s perspective, but also for health
care planning, conditional estimates are of great importance since the prognosis changes
substantially within the first few years after a colon cancer diagnosis.
Based on the period analysis, the total estimated number of life years lost for Swedish
colon cancer patients diagnosed in 2011 will be 21 252 years. This number was estimated to
be 20 461 if males were given the same colon cancer mortality as females, giving a potential
gain of 791 life years. On the individual level this gain would give 0.75 years longer life
expectancy for males aged 55 at diagnosis if they had the same cancer patient mortality as
females aged 55 at diagnosis, whereas this number is 0.64, 0.36 and 0.11 years for 65, 75 and
85 year old males, respectively.
Sensitivity analysis
A sensitivity analysis was carried out to see how robust the estimates were to the number
of knots used for the time-scale as well as for the effect of age and calendar year. This was
not included in the paper due to the length requirements of most journals. The main model
in this study had 5 degrees of freedom for the baseline log cumulative hazard, 3 degrees of
freedom for time-varying effects and both the age and calendar year splines had 4 degrees
of freedom. For the sensitivity analysis, four extra models were fitted, one with 4 degrees of
40
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Figure 12 – Temporal trends in life expectancy from diagnosis for colon cancer patients
diagnosed in Sweden during 1961–2011.
freedom for the baseline, one with 6 degrees of freedom for the baseline, one with 3 degrees of
freedom for the effect of age and calendar year and finally one with 5 degrees of freedom for
the effect of age and calendar year. Estimates of the loss in expectation of life from the main
analysis and the four sensitivity analysis are presented in figure 14 and 15 for two selected
ages and 5 selected years.
The estimates of loss in expectation of life seem to be robust to the number of knots, but
41
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Figure 13 – Loss in expectation of life conditional on time since diagnosis for colon cancer
patients diagnosed in Sweden during 1961-2011.
we also wanted to investigate how much small variations impact on the total number of life
years lost. Therefore the period analysis was also repeated with 4 degrees of freedom for the
baseline, 6 degrees of freedom for the baseline and 5 degrees of freedom for the age effect.
The total number of life years lost for patients diagnosed in 2011, estimated from the three
sensitivity analyses, ranged from 21 219 to 21 254.
42
Conclusion
Improved life expectancy was observed for colon cancer patients during the 50 year period
under study, but the increase mimicked the improved life expectancy in the general popu-
lation. Young colon cancer patients have a longer life expectancy, but are also expected to
lose more years of their life compared to older colon cancer patients. A similar result was
observed for female colon cancer patients who have a longer life expectancy but also lose
more years than males. However, for all calendar years, all ages and for both males and
females the loss in expectation of life decreases substantially when conditioning on survival
up to a few years after diagnosis. In summary, life expectancy and loss in expectation of
life improves the understanding of the impact of cancer and gives a good complement to
RSR for understanding the prognosis of cancer patients. In this population-based study we
demonstrated how summarizing colon cancer survival in terms of loss in expectation of life
can be useful in order to gain further insights of the impact of colon cancer on both the indi-
vidual and population level by examining temporal trends, changes by time since diagnosis
and quantifying differences between males and females.
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7 Conclusion and future perspective
Alternative measures of cancer patient survival are needed to gain further insights into
cancer patient survival, and in this thesis I have focused on estimation of cure and loss
in expectation of life among cancer patients. By the use of different measures, a lot more
can be understood about different aspects of the prognosis of cancer patients, and different
consumers of survival statistics need different measures to serve their different questions. In
paper I the estimation of the proportion cured, along with median survival time of uncured,
enhanced the understanding of temporal trends in AML patient survival and the impact of
treatment changes over time. In paper IV life expectancy and loss in expectation of life was
used as a complement to 5-year RSRs to quantify the survival of colon cancer patients. Paper
I and IV were applications of methods for estimating cancer patient survival, and the aim was
to gain insights into the prognosis of AML patients and colon cancer patients as well as to
present the measures to a broader research community. Paper II and III concerned methods
development and extensions, and were published in statistical journals. In paper II a flexible
parametric cure model that overcomes some of the limitations of standard parametric cure
models was developed. The possibilities of using a flexible parametric relative survival model
for extrapolating survival and therefore estimating life expectancy and loss in expectation
of life were evaluated in paper III. Evaluations of the methods presented in this thesis were
included in the published papers, and selected parts also included in section 6, but more
evaluations and further extensions are warranted. A few thoughts on possible extensions
and further evaluations are presented in this section.
Flexible parametric cure model
A recent study by Yu et al. [85] comparing cure models came to the conclusion that the
flexible parametric cure models give valid estimates of cure, and should be preferred over
many parametric cure models. What the study did not include was an evaluation of how
well the flexible parametric cure model estimates the survival of uncured. This has however
been studied in a master thesis from the University of Leicester [86], although the results
have not been published. The thesis showed that even though the flexible parametric cure
model gives estimates with negligible bias of the cure proportion and the median survival
time of uncured there was small bias in the estimation of, for example, the time point where
90% of uncured had died. This is probably due to the restriction put on the splines in the
flexible parametric cure model. As described in section 4.3, when the cumulative excess
hazard is forced to be constant after the last knot, the shape of the cumulative excess hazard
is also slightly changed before the position of the last knot, due to the smoothness of the
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splines. This could potentially be improved by the use of the more flexible splines with
relaxed smoothness at the last knot, described in the same section. We are planning to
conduct a simulation study to investigate if the fit is improved by using the more flexible
splines, under different scenarios.
The study by Yu et al. also included a sensitivity analysis of the robustness to the choice
of knots in the flexible parametric cure model. As described in section 2.6, the flexible
parametric survival model has been shown to be robust to the number and location of the
knots, but this is not necessarily true when a cure point is imposed. The shape of the baseline
log cumulative excess hazard can easily be captured using restricted cubic splines, since the
log cumulative excess hazard is a fairly stable function. However, it is not obvious that
restricted cubic splines fit the data as well when the spline is manipulated to force a zero
slope after the last knot. Another issue is that to give a good estimate of the cure proportion,
the splines need to fit the data well towards the end of follow-up, even though most events
are observed early in the follow-up. The sensitivity of the flexible parametric cure model to
the knot distribution was also examined in paper II. Both sensitivity analyses showed that
the flexible parametric cure model is robust to the knot distribution as long as there are
enough knots towards the end of follow-up. Therefore, the default knot distribution for the
stpm2 command includes one knot at the 95th as well as the 100th percentile of event times
when a flexible parametric cure model is fitted [64].
The flexible parametric cure model is a restricted flexible parametric survival model,
where one of the spline parameters is set to 0. Because of this, the flexible parametric cure
model is nested within a flexible parametric survival model, and the assumption of cure can
therefore be tested using a likelihood ratio (LR) test. This was discussed in paper II, where
we also showed the practical limitations of this approach. There is a general problem with
the use of LR tests or other likelihood based comparison criteria (such as Akaike information
criterion (AIC) and Bayesian information criterion (BIC)) for cure models, since more weight
is given to the fit early in follow-up since that is where most events occur. A model with a
poorly estimated cure proportion could fit slightly better in the beginning of follow-up and
therefore be chosen over a model with a better estimate of cure. An example of this was
presented by Lambert et al. [39] where a non-mixture model with a log-normal distribution
gives a lower AIC than a non-mixture model with Weibull distribution, although it is clear
that the Weibull non-mixture model gives a better estimate of the cure proportion. This
is especially problematic in the type of population-based studies that are presented in this
thesis, since the large data sets with many events will easily give significant results even for
very small differences. When using a cure model we are generally willing to give up some
model fit early on in follow-up in order to gain the extra information that a cure model
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can provide. We would therefore often chose to use a cure model even if a LR test would
suggest that a model without a cure point gives a slightly better fit. We recommend that
the existence of a cure point is evaluated by plotting empirical life table estimates of relative
survival, and that cure models should not be used if the relative survival does not reach a
plateau within the available follow-up. A log-rank type test for testing the existence of cure
in a relative survival setting has also been proposed [87]. A possible further extension of the
flexible parametric cure model could be to use a likelihood approach that gives more weight
to the end of follow-up, and by that enable comparison to a flexible parametric survival
model without cure.
A difference between the flexible parametric cure model and the other cure models de-
scribed in this thesis is that the point of cure is specified in the flexible parametric cure model
by the position of the final knot. When the cure proportion is estimated as an asymptote
of the survival function, as for the mixture and non-mixture cure model, the cure point is
effectively at infinity. This feature of the cure models could be seen as both an advantage
and a disadvantage. By explicitly specifying the point of cure in the flexible parametric cure
model (by the position of the last knot), the cure proportion could be grossly overestimated
if the last knot is placed too early, if the survival function has not yet reached a plateau. On
the other hand, estimating the cure point itself could be of interest and by comparing models
with the last knot placed at different time points one could potentially get an estimate of
the time of cure. This however needs further work and evaluation. Even though it could
theoretically be done, in practice it is difficult to compare models in this way. Comparisons
of cure models with the last knot at different positions is difficult for the reasons described
above, another reason is that the flexible parametric survival model is robust to the positions
of the knots, so small changes in the knot position will only lead to small changes in model
fit and therefore this approach is unlikely to be useful for predicting time of cure.
I believe that cure models are a very useful tool, and hope that the flexible parametric
cure model will lead to more use of the cure proportion as an estimate of long-term survival.
The main advantages of the flexible parametric cure model is that it allows inclusion of
patient groups for which parametric cure models do not converge or do not give a good
fit. We have, for example, used the flexible parametric cure model to study how the cure
proportion and median survival time of uncured differs by age, stage, location and sex for
patients with malignant melanoma. This was not possible to do with a Weibull mixture or
non-mixture cure model because the models wouldn’t converge. Malignant melanoma is a
cancer with relatively high survival, and in our experience the Weibull mixture and non-
mixture cure models do not always converge when the relative survival is high. In summary,
the flexible parametric cure model is a good alternative to the mixture and non-mixture cure
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models, but further evaluations are needed.
Life expectancy and loss in expectation of life
The loss in expectation of life is theoretically easy to estimate, but in practice there are
complications because of limited follow-up. Therefore, the key feature of a method used
to estimate the loss in expectation of life is that the observed survival can be satisfactorily
extrapolated beyond the available follow-up. In paper III it was shown that a flexible para-
metric relative survival model can be used, and the extrapolated survival agreed very well
with the observed survival. In that study all patients diagnosed at ages younger than 50
were excluded, since the available 40 years of follow-up was not enough to estimate their
mean survival time. The extrapolation might not perform as well for younger patients both
since it is a smaller group and since the extrapolation needs to be done over a longer period,
and it has also been argued that long-term excess mortality among patients diagnosed at a
young age may have a large impact on mortality in later ages [88]. Further evaluations of
extrapolations of the flexible parametric relative survival model are therefore needed in order
to know how well they can be applied for estimating the life expectancy of younger cancer pa-
tients. It would also be interesting to see how well the models extrapolate survival in smaller
data sets such as clinical trials, and if this approach could be a complement to methods
often used to compare treatment groups. Because of the limited follow-up, restricted mean
survival times are often presented, and Royston and Parmar [89] suggested the use of flexible
parametric models. Andersen suggested a way of dividing the number of life years lost within
a restricted time interval according to different causes of death using competing risks meth-
ods [90]. However, it would be interesting to calculate the full life expectancy rather than
the restricted, since differences in the restricted mean survival between treatment groups
can never fully estimate the impact of treatment differences on survival. Another potential
area where this approach could be used is for economic evaluations and cost-effectiveness
studies. Tappenden et. al argue that alternative extrapolation methods are needed in cost-
effectiveness studies [91]. Some methods have been proposed, such as poly-Weibull models
[92] or Bayesian evidence synthesis of data from a variety of sources [93], but evaluations of
these methods have not been performed on data with complete follow-up.
Not only the observed survival, but also the expected survival has to be extrapolated.
In both paper III and IV we assumed that the population mortality rates stayed constant
after the last available calendar year in the population mortality files (1980 in paper III
and 2011 in paper IV). Even so, the extrapolations made in paper III agreed very well
with the observed mean survival time. Statistics Sweden has published projections of the
Swedish population mortality [94] , and when available one should consider using projections
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Table 2 – Estimated life years lost for colon cancer patients diagnosed in Sweden during 2011,
using two different assumptions about future population mortality rates.
Estimated life years lost Estimated life years lost
from paper IV assuming constant using projection of future population
population mortality rates after 2011 mortality rates from Statistics Sweden
Age Males Females Males Females
55 10.7 11.3 12.2 12.3
65 7.12 7.66 8.02 8.40
75 4.00 4.50 4.40 4.88
85 1.77 2.05 1.86 2.18
Total in
population 10580 10672 11843 11637
of population mortality when future mortality is needed. We reproduced the predictions
from the period analysis in paper IV using the future population mortality projections from
Statistics Sweden, and the results are shown in table 2. The estimated loss in expectation of
life is higher if projections of future population mortality rates are used, since the mortality
rate in Sweden is expected to be decreasing. Even so, one has to keep in mind that the
projections are also estimates.
Another issue with the use of population mortality rates is if the expected rates can
be considered to be fixed, or if they should be considered random. In many applications of
relative survival the expected survival can be considered fixed since it is based on such a large
population so that random variation is negligible. However, if the population mortality file
is broken down by many factors or is specific for a small region one has to start considering
if the assumption is still valid. Seppa¨ et al. incorporated the uncertainty of the population
mortality into their estimation in a study focusing on regional variation in cancer patient
survival in Finland [95], but it did not have a large impact on the estimates or their standard
errors. Another reason for taking the variation of the population mortality into account is
when estimates of the expected survival are of specific interest and not only for estimation
of relative survival. This is the case when estimating the loss in expectation of life, since it
requires the estimation of life expectancy in the absence of cancer, obtained from population
mortality rates. For the estimation of the loss in expectation of life, we only consider the life
expectancy in the presence of cancer as random and assume that we can correctly estimate
the life expectancy in the absence of cancer without any variation. In order to understand
how large the impact of this is on the variance of the loss in expectation of life, further
analysis is needed where the variation in the life expectancy in the absence of cancer is
taken into account. Another, and easier, approach to reduce the variation in the population
mortality would be to smooth the population mortality rates. Although, this approach still
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assumes that there is no random variation in the estimation of expected survival for the
cancer patients.
A potential important use of the loss in expectation of life is to quantify differences
between groups. It is of major public health interest to be able to quantify differences
between, for example, socio-economic groups, and the number of life years lost is one possible
measure which is easily interpreted. During the last few years there has been a great interest
in quantifying differences in cancer patient survival between countries in other ways than
by comparing the 5- or 10-year RSR, and the number of avoidable deaths has been used
[96, 97, 98, 99]. A disadvantage of avoidable deaths is that the measure is highly time-
dependent, since deaths can only be postponed and not avoided in the long run. We believe
that this is an area where the loss in expectation of life could be used instead to better
quantify the impact of differences in cancer patient survival between countries or between
groups in the population.
Final words
In summary, the methods presented in this thesis are additional tools for estimating and
quantifying population-based cancer patient survival using routinely collected cancer reg-
istry data. They can hopefully lead to a further understanding of different aspects of cancer
patient survival, and how cancer patient survival differs between groups. By the implemen-
tation of the methods in user-friendly software we have enabled others to use the methods,
and applications of the methods will hopefully increase the awareness of these and other
alternative measures of cancer patient survival.
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